Leaders from across the healthcare ecosystem came together to share insights, shape policy, and spotlight groundbreaking innovation.

A recent op‑ed in The Washington Times , titled “No Global Freeloading on Medical Innovation”  and authored by the executive director of the Washington Healthcare Innovation Council (WHIC), highlights a critical issue in global healthcare policy. The piece emphasizes that while the U.S. drives a majority of medical innovation, other countries often impose strict price controls or undervalue groundbreaking therapies, effectively allowing them to benefit from American R&D witho

From FDA leaders outlining bold reforms, to former HHS Secretary Alex Azar and Congressman Gus Bilirakis sharing their vision for innovation and access, this week’s WHIC gathering brought together the voices shaping the future of American health care.

On June 10, the Washington Health Innovation Council (WHIC) hosted a very special meeting that brought together leaders from Congress,...

At our recent WHIC forum, Darcie Johnston of HHS briefed attendees on the newly released MAHA Commission Report, including the removal of COVID vaccine requirements for healthy pregnant women and children. The discussion highlighted a shift under new leadership toward evidence-based policies and innovative tools like therapeutics and AI-enabled diagnostics—focusing on protecting vulnerable populations without non-science-based mandates.

At our April 23 forum, WHIC members and partners convened to tackle timely issues—from executive orders and budget challenges to tariffs and HHS appointments—while spotlighting innovators like SeaStar Medical and hearing expert perspectives from AdvaMed and author Tevi Troy. The discussions underscored WHIC’s role as a hub for candid dialogue at the intersection of policy, industry, and innovation.

The Boston Herald  recently published an op‑ed titled “Biden’s Pill Penalty Hurts Us All,”  penned by Kalavritinos, which argues that recent drug policy changes impose hidden costs that damage the whole American healthcare system. The article contends that pricing restrictions, regulatory burdens, and penalties on pharmaceutical innovation will discourage investment in next‑generation therapies. It warns these economic disincentives not only slow progress on new drugs, but al

Washington Health Innovation Council Releases Comprehensive Report On The Dangers Of Third-Party Litigation Funding On American Patients

Washington Health Innovation Meeting Recap - January 30th, 2025 The first Washington Health Innovation Council (WHIC) meeting...

Thank you to all our JKS partners and friends for joining us for our annual holiday gathering!

July 2024 | Washington D.C. -- Throughout 2024 the Washington Health Innovation Council (WHIC) has featured challenges facing the rare...

June 26, 2024 Washington D.C. -- The WHIC had a serious set of discussions revolving around the IP confiscation proposal, the U.S Chamber...

June 26, 2024 | Washington D.C. -- The WHIC had a serious set of discussions revolving around the IP confiscation proposal, the U.S...

May 20, 2024 Washington, D.C.-- At the DC headquarters of the American Academy of Ophthalmology, our Washington Health Innovation...

WHIC's recent discussion about rare diseases and the promise and the hurdles was both powerful and disheartening.